Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioStem Technologies, Inc.BSEM · Entity 7054 | Chief Accounting Officer | September 15, 2026 | September 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioStem Technologies, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,664 |
Reported balance
After 2026-09-15 transaction · row 1
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 4,234 · Balance 68,664 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 16,941 |
Reported balance
After 2026-09-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-15 · Exercise / conversion · Disposed 4,234 · Balance 16,941 F6: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,790 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 6,790 F6: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F8: These restricted stock units vest according to the following schedule: 33% vested on May 9, 2026, the one-year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 31,818 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 31,818 F6: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F9: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2027-08-16 | Direct | 200,000 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 200,000 F1: These options are fully vested and exercisable. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2033-01-04 | Direct | 100,000 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 100,000 F2: These options vest according to the following schedule: 25% vested on January 4, 2024, the one year anniversary of the grant date, with the remaining options vesting in equal monthly installments over the subsequent three year period. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.11 · Expires 2035-05-09 | Direct | 11,582 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 11,582 F3: These options vest according to the following schedule: 33% vested on May 9, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.11 · Expires 2035-10-13 | Direct | 2,340 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 2,340 F4: These options vest according to the following schedule: 33%% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2036-02-11 | Direct | 38,546 |
Reported balance
Holding disclosure · report date 2026-09-15 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 38,546 F5: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
Filing footnotes · ownership attribution and instrument terms
F1: These options are fully vested and exercisable.
F2: These options vest according to the following schedule: 25% vested on January 4, 2024, the one year anniversary of the grant date, with the remaining options vesting in equal monthly installments over the subsequent three year period.
F3: These options vest according to the following schedule: 33% vested on May 9, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F4: These options vest according to the following schedule: 33%% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F5: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F6: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F7: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024).
F8: These restricted stock units vest according to the following schedule: 33% vested on May 9, 2026, the one-year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
F9: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 4,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394388 · ownership.xml · derivative · entry 7 FORTUNATO MICHAEL A · CIK 0002147232 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,941 Underlying: Common Stock · 4,234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024). F7 · derivative.expiration_date: These restricted stock units vest in equal quarterly installments over three years from the grant date (September 15, 2024). Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 4,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394388 · ownership.xml · nonDerivative · entry 1 FORTUNATO MICHAEL A · CIK 0002147232 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2026 Filed Aug 20, 2026 23:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 970 | $0.00 | $0.00 |
DisclosureSEC source: 0002147232-26-000006 · ownership.xml · derivative · entry 8 FORTUNATO MICHAEL A · CIK 0002147232 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,790 Underlying: Common Stock · 970 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F8 · derivative.exercise_date: These restricted stock units vest according to the following schedule: 33% vested on May 9, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period. Due to an administrative error, the vesting of the restricted stock units was not timely reported on a Form 4 within two business day of the applicable transaction date. F8 · derivative.expiration_date: These restricted stock units vest according to the following schedule: 33% vested on May 9, 2026, with the remaining units vesting in equal quarterly installments over the subsequent two year period. Due to an administrative error, the vesting of the restricted stock units was not timely reported on a Form 4 within two business day of the applicable transaction date. Read SEC document |
| August 09, 2026 Filed Aug 20, 2026 23:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 970 | $0.00 | $0.00 |
DisclosureSEC source: 0002147232-26-000006 · ownership.xml · nonDerivative · entry 1 FORTUNATO MICHAEL A · CIK 0002147232 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.